Navigation Links
New Agreements and Stock Movements in Healthcare Companies - Research Report on Abbott, Thermo Fisher, Intuitive Surgical, Mindray, and Zeltiq
Date:11/27/2013

NEW YORK, November 27, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Abbott Laboratories (NYSE: ABT),

Thermo Fisher Scientific Inc. (NYSE: TMO), Intuitive Surgical, Inc. (NASDAQ: ISRG), Mindray Medical International Ltd (NYSE: MR), and Zeltiq Aesthetics Inc. (NASDAQ: ZLTQ). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Abbott Laboratories Research Report

On November 22, 2013, stocks of Abbott Laboratories (Abbott) rose 0.47% to $38.25 at the end of trading. Over the previous three trading sessions, Abbott's shares slipped by 1.19% when compared to the Dow Jones Industrial Average which rose 0.61% during the same period. The Full Research Report on Abbott Laboratories - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05c1_ABT

--

Thermo Fisher Scientific Inc. Research Report

On November 21, 2013, Reuters reported that Thermo Fisher Scientific Inc. (Thermo Fisher) and OraSureTehcnologies Inc. have entered into a new agreement. Reuters informed that the said agreement is for the development and distribution of fully automated oral fluid drugs of abuse assays, in which a NIDA-5 panel of assay is expected to be initially sold starting in H2 2014. The Full Research Report on Thermo Fisher Scientific Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/45ed_TMO

--

Intuitive Surgical, Inc. Research Report

On November 22, 2013, stocks of Intuitive Surgical, Inc. (Intuitive Surgical) slipped 0.21% to $389.71 at the end of trading. Shares of Intuitive Surgical dropped 1.23% over the past three trading sessions, while the Nasdaq composite rose 1.53% during the same period. The Full Research Report on Intuitive Surgical, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/5f98_ISRG

--

Mindray Medical International Ltd Research Report

On November 22, 2013, Mindray Medical International Ltd's (Mindray) shares ended at $39.45, indicating a 1.55% drop. Over the past three trading sessions, shares of Mindray went up 2.07% while the Dow Jones Industrial Average also rose 0.61% during thE same period. The Full Research Report on Mindray Medical International Ltd - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/8d4d_MR

--

Zeltiq Aesthetics Inc Research Report

On November 22, 2013, shares of Zeltiq Aesthetics Inc (Zeltiq) rose 6.91% to $16.71 at the end of trading. Over the past three trading sessions, shares of Zeltiq soared 11.47% while the Nasdaq composite also rose 1.53% during thE same period. The Full Research Report on Zeltiq Aesthetics Inc - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/b15b_ZLTQ

----

EDITOR NOTES:

  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://AnalystsCorner.com

 


'/>"/>
SOURCE Analysts' Corner
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
2. Financial Results, Agreements, Meetings, and Clinical Trials - Research Report on Cell Therapeutics, Akorn, Ligand, Intercept Pharmaceuticals and Ariad Pharmaceuticals
3. Sequenom Announces License And Marketing Agreements With Laboratoire Cerba In France
4. NxStage Announces New Agreements with DaVita
5. Cancer Vaccine Partnering Terms and Agreements
6. Allergans Global Dominance in Facial Injectables Challenged by Acquisitions and Partnership Agreements Among Competitors
7. Novation Awards Cardiovascular Agreements
8. Lifecycle Management Strategies: Pharma-Payer Deals - Creative agreements are used at different stages of the brand lifecycle to maximize sales
9. Sequenom Completes International Distribution Agreements To Expand Access To MaterniT21 PLUS Prenatal Testing Service
10. BioDrain Medical Inc. Signs Additional Independent Distribution Agreements, Strengthening Nationwide Presence
11. Vaccine Partnering Terms and Agreements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... , Feb. 4, 2016 Worldwide Radiology ... significant growth as next generation systems provide a ... radiology for cancer surgery. New systems pinpoint the ... that has been such a problem previously, limiting ... Radiosurgery robots take cancer surgery far beyond what ...
(Date:2/4/2016)... LONDON , Feb. 4, 2016 ... Summary Global Markets Direct,s, ,Wegener Polyangiitis - ... the Wegener Polyangiitis,s therapeutic pipeline. This report ... Wegener Polyangiitis, complete with comparative analysis at various ... action (MoA), route of administration (RoA) and molecule ...
(Date:2/4/2016)... , Feb. 4, 2016 Global ... competitive market to drive long-term market growth ... common set of chronic disorders that affect 5–7% ... in terms of their symptoms and key patient ... dysregulation of immune pathways and an inappropriate immune ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific Officer ... use newly released government data on populations and physicians to better calculate risk ... the value they create to succeed in new economic models for value based ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online for ... 2016 Conference, which is being held May 25-29 at the Loews Chicago O’Hare Hotel, ... interventions and causes of chronic illness in children. , Very recent articles have cited ...
(Date:2/7/2016)... Lake Orion, Clarkston, Metamora, Michigan (PRWEB) , ... ... ... ability to correct pelvic organ prolapse with the latest techniques and the most ... greatest risk for pelvic organ prolapse, particularly after menopause. Other risk factors include ...
(Date:2/7/2016)... ... February 07, 2016 , ... HealthSmart Holdings, Inc. ... organizations with the tools and information to lower the costs, and increase the ... cost of providing employee healthcare benefits by as much as 22%:, + ...
(Date:2/6/2016)... ... February 06, 2016 , ... ... NURSES EXPECTED AT AORN SURGICAL CONFERENCE & EXPO , WHAT:     , This ... an estimated 5000 perioperative nurses in attendance to study the latest evidence-based ...
Breaking Medicine News(10 mins):